Report from the Annual General Meeting in Bluefish Pharmaceuticals AB
The Annual General Meeting in Bluefish Pharmaceuticals AB was held on 16 June 2015 at 15.00 (CET) in Stockholm
At the Annual General Meeting the following decisions were passed;
- to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet.
- to adopt the allocation of the company’s profits.
- to release the Directors and the CEO from liability.
- that the number of permanent directors shall be four without deputy directors.
- that the Board of Directors shall consist, until the end of the annual general meeting in 2016, of the following directors:
- Erika Kjellberg Eriksson (permanent director)
- Gerald Engström (permanent director)
- Karl Karlsson (permanent director)
- Nivedan Bharadwaj (permanent director)
- to elect EY AB as the company’s auditor for a period of one year, until the end of the next Annual General Meeting in 2016.
- to approve the Board of Director’s proposal regarding the Annual General Meeting authorising the Board to issue a total of 10 000 000 B shares.
For more information, contact
Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: karl.karlsson@bluefishpharma.com
Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: susanna.urdmark@bluefishpharma.com
About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of approximately 80 products and is growing.
www.bluefishpharma.com